CompanyDeals

Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses

CompanyDrug

Kangtai Biological Initiates Phase I Clinical Study for Trivalent Influenza Split Vaccine Produced in MDCK Cells

CompanyDeals

AbbVie Announces $1.4 Billion Advanced Manufacturing Campus in North Carolina to Support Immunology, Neuroscience, and Oncology Portfolio

CompanyDeals

Merck & Co. Announces $1 Billion Strategic Partnership with Google Cloud to Deploy Enterprise-Wide Agentic AI Platform

FDA Expands Sanofi's Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention
CompanyDrug

FDA Expands Sanofi’s Tzield Approval to Children as Young as One Year Old for Type 1 Diabetes Prevention

Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance
Company

Boston Scientific Reports Strong Q1 2026 Results with 9.4% Net Sales Growth; Cardiovascular Segment Leads Performance

European Commission Grants Conditional Approval to Ipsen's Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations
CompanyDrug

European Commission Grants Conditional Approval to Ipsen’s Ojemda (Tovorafenib) for Pediatric Low-Grade Glioma with BRAF Alterations

Johnson & Johnson Secures CE Mark for Advanced ETHICON 4000 Surgical Stapler with Proprietary 3D Stapling Technology
CompanyMedical Device

Johnson & Johnson Secures CE Mark for Advanced ETHICON 4000 Surgical Stapler with Proprietary 3D Stapling Technology

FDA Approves Sanofi-Regeneron's Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2–11 Years
CompanyDrug

FDA Approves Sanofi-Regeneron’s Dupilumab for Pediatric Chronic Spontaneous Urticaria in Children Aged 2–11 Years

CompanyDrug

China’s CDE Releases 106th Batch of Chemical Generic Reference Preparations with 27 New Specifications and Updated Guidelines

FDA Extends Review Timeline for Sanofi's Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026
CompanyDrug

FDA Extends Review Timeline for Sanofi’s Sarclisa Subcutaneous Formulation by Three Months; New Decision Date Set for July 23, 2026

Policy / Regulatory

NMPA Suspends Colchicine API Imports from Indian Manufacturers Alkaloids Bioactives and Alchem International Over Change Management Violations